KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Non-Current Assets for 16 consecutive years, with -$825.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 184.37% to -$825.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 billion, a 47.6% decrease, with the full-year FY2025 number at -$825.2 million, down 184.37% from a year prior.
  • Non-Current Assets was -$825.2 million for Q4 2025 at Halozyme Therapeutics, down from $978.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.2 billion in Q3 2022 to a low of -$825.2 million in Q4 2025.
  • A 5-year average of $427.9 million and a median of $178.1 million in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 620.52% in 2022, then plummeted 184.37% in 2025.
  • Halozyme Therapeutics' Non-Current Assets stood at $178.1 million in 2021, then soared by 518.89% to $1.1 billion in 2022, then decreased by 10.49% to $986.8 million in 2023, then dropped by 0.88% to $978.1 million in 2024, then tumbled by 184.37% to -$825.2 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Non-Current Assets are -$825.2 million (Q4 2025), $978.1 million (Q4 2024), and $986.8 million (Q4 2023).